Lipid Lowering Oxopropanylindole Hydrazone Derivatives with Anti-oxidant and Anti-hyperglycemic Activity

被引:3
作者
Varshney, Kanika [1 ]
Gupta, Amit K. [2 ]
Sonkar, Ravi [3 ]
Varshney, Salil [4 ]
Mishra, Akanksha [3 ]
Bhatia, Geetika [3 ]
Gaikwad, Anil [4 ]
Srivastava, Arvind Kumar [3 ]
Saxena, Mridula [5 ]
Jain, Sudha [6 ]
Saxena, Anil K. [1 ]
机构
[1] Cent Drug Res Inst, Med & Proc Chem Div, Lucknow 226031, Uttar Pradesh, India
[2] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA
[3] Cent Drug Res Inst, Biochem Div, Lucknow 226031, Uttar Pradesh, India
[4] Cent Drug Res Inst, Pharmacol Div, Lucknow 226031, Uttar Pradesh, India
[5] Amity Univ, Dept Chem, Lucknow, Uttar Pradesh, India
[6] Lucknow Univ, Dept Chem, Lucknow 226007, Uttar Pradesh, India
关键词
Hydrazone derivatives; Anti-oxidant; Anti-dyslipidemic; Atherosclerosis; Lipid; Anti-hyperglycemic; LOW-DENSITY-LIPOPROTEIN; CORONARY-HEART-DISEASE; ATHEROSCLEROSIS; IDENTIFICATION; CHOLESTEROL; LIPASE; INHIBITORS; PROTEIN; HDL;
D O I
10.2174/1568026619666181220112903
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A series of substituted oxopropanylindole hydrazone derivatives was synthesized and evaluated for anti-oxidant and anti-dyslipidemic activity. Of the 12 tested, 3 compounds (6c, 7b and 7d) showed good anti-oxidant activity, compound 6c attenuated LDL oxidation by 32%. The compounds 6c and 7d also showed good anti-dyslipidemic activity by reducing serum levels of total cholesterol (TC), phospholipids (PL) and triglycerides (TG). These two compounds were further evaluated for anti-adipogenic and anti-hyperglycemic activity, where 6c showed 44% reduction in lipid accumulation and 20.5% and 24.3% reduction in blood glucose at 5h and 24h respectively, as compared to standard drug metformin. Thus, compounds 6c and 7d with balanced anti-oxidant and anti-dyslipidimic activities may be excellent candidates for lead optimization and drug development for the treatment of metabolic disorders.
引用
收藏
页码:2256 / 2265
页数:10
相关论文
共 37 条
[1]   IMPAIRED ACTIVATION OF GLUCOSE-OXIDATION AND NADPH SUPPLY IN HUMAN ENDOTHELIAL-CELLS EXPOSED TO H2O2 IN HIGH-GLUCOSE MEDIUM [J].
ASAHINA, T ;
KASHIWAGI, A ;
NISHIO, Y ;
IKEBUCHI, M ;
HARADA, N ;
TANAKA, Y ;
TAKAGI, Y ;
SAEKI, Y ;
KIKKAWA, R ;
SHIGETA, Y .
DIABETES, 1995, 44 (05) :520-526
[2]   MODIFIED FORMS OF LOW-DENSITY-LIPOPROTEIN AND ATHEROSCLEROSIS [J].
AVIRAM, M .
ATHEROSCLEROSIS, 1993, 98 (01) :1-9
[3]   REGULATION OF THE SYNTHESIS, PROCESSING AND TRANSLOCATION OF LIPOPROTEIN-LIPASE [J].
BRAUN, JEA ;
SEVERSON, DL .
BIOCHEMICAL JOURNAL, 1992, 287 :337-347
[4]  
Bruce C, 1998, J LIPID RES, V39, P1071
[5]  
BUCOLO G, 1973, CLIN CHEM, V19, P476
[6]   ANTIOXIDANT ACTIVITIES OF SOME TRYPTOPHAN-METABOLITES - POSSIBLE IMPLICATION FOR INFLAMMATORY DISEASES [J].
CHRISTEN, S ;
PETERHANS, E ;
STOCKER, R .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (07) :2506-2510
[7]   Type 2 Diabetes Mellitus and Cardiovascular Disease: Genetic and epigenetic Links [J].
De Rosa, Salvatore ;
Arcidiacono, Biagio ;
Chiefari, Eusebio ;
Brunetti, Antonio ;
Indolfi, Ciro ;
Foti, Daniela P. .
FRONTIERS IN ENDOCRINOLOGY, 2018, 9
[8]  
DEEG R, 1983, CLIN CHEM, V29, P1798
[9]   Effect of bezafibrate treatment over five years on coronary plaques causing 20% to 50% diameter narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]) [J].
Ericsson, CG ;
Nilsson, J ;
Grip, L ;
Svane, B ;
Hamsten, A .
AMERICAN JOURNAL OF CARDIOLOGY, 1997, 80 (09) :1125-1129
[10]   A novel Lipoprotein lipase (LPL) agonist rescues the enzyme from inhibition by angiopoietin-like 4 (ANGPTL4) [J].
Geldenhuys, Werner J. ;
Aring, Danielle ;
Sadana, Prabodh .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (09) :2163-2167